Possible side effects and complications of Quizartinib

Quizartinib (Quizartinib) is a targeted treatment drug for acute myeloid leukemia (AML) with FLT3-ITD mutation. Although it shows high efficacy, its use may still be accompanied by a series of side effects and potential complications, which are mainly related to the drug's inhibition of tyrosine kinase activity. The most common adverse reactions include bone marrow suppression, cardiac arrhythmias, gastrointestinal symptoms, and fatigue. Myelosuppression manifests as neutropenia, thrombocytopenia, and anemia, which may increase the risk of infection, bleeding, or cause significant fatigue. Regular blood routine monitoring is required, and if necessary, intervention through supportive treatment such as blood transfusion or use of growth factors.

In terms of heart, Quizartinib may causeQT interval prolongation, which is a cardiac electrophysiological change that can increase the risk of arrhythmia if not monitored in time. Patients need to undergo electrocardiogram examinations before and during treatment, especially patients who are combined with other QT prolonging drugs or have a history of cardiovascular disease, and should be more cautious. Some patients may also experience gastrointestinal discomfort such as nausea, vomiting, diarrhea, oral ulcers, or loss of appetite. Such symptoms can usually be alleviated through dietary adjustments or symptomatic drugs.

In addition, fever, headache, arthralgia, or mild liver function abnormalities may occur occasionally with quizartinib, requiring regular monitoring of liver enzyme levels. When used for a long time or at high doses, electrolyte imbalance or decreased immune function may also occur, increasing the risk of infection. Therefore, during the use of quizartinib, it is recommended that patients undergo full monitoring under the guidance of a professional physician, including blood routine, electrolytes, liver and kidney function, and electrocardiogram, in order to promptly detect and deal with adverse reactions and complications.

Overall, the side effects of quizartinib were predictable and manageable. Through strict dose management, regular laboratory examinations and symptom monitoring, most side effects can be detected and dealt with early, thereby minimizing risks while ensuring efficacy.

Reference materials:https://go.drugbank.com/drugs/DB12874